Agenus Inc
NASDAQ:AGEN

Watchlist Manager
Agenus Inc Logo
Agenus Inc
NASDAQ:AGEN
Watchlist
Price: 3.91 USD 4.27% Market Closed
Market Cap: 133m USD

Net Margin
Agenus Inc

-33.1%
Current
-188%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.1%
=
Net Income
-35.4m
/
Revenue
106.8m

Net Margin Across Competitors

No Stocks Found

Agenus Inc
Glance View

Market Cap
128.3m USD
Industry
Biotechnology

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

AGEN Intrinsic Value
13.42 USD
Undervaluation 71%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.1%
=
Net Income
-35.4m
/
Revenue
106.8m
What is the Net Margin of Agenus Inc?

Based on Agenus Inc's most recent financial statements, the company has Net Margin of -33.1%.

Back to Top